Prolixin

Chorea, Depression, Sedation + 4 more

Treatment

1 FDA approval

20 Active Studies for Prolixin

What is Prolixin

Fluphenazine

The Generic name of this drug

Treatment Summary

Phenothiazine is an antipsychotic drug that is used to treat mental illnesses such as psychosis. It works in a similar way to chlorpromazine, another type of antipsychotic medicine.

Fluphenazine Hydrochloride

is the brand name

image of different drug pills on a surface

Prolixin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Fluphenazine Hydrochloride

Fluphenazine

1987

181

Approved as Treatment by the FDA

Fluphenazine, also known as Fluphenazine Hydrochloride, is approved by the FDA for 1 uses including Schizophrenia .

Schizophrenia

Helps manage Psychosis

Effectiveness

How Prolixin Affects Patients

Fluphenazine is a medication used to treat schizophrenia and other mental disorders. It has not been found to be effective in treating behavior problems in people with intellectual disabilities.

How Prolixin works in the body

Fluphenazine works by blocking receptors in the brain that are related to dopamine. This has the effect of reducing hormones in the hypothalamus and pituitary gland as well as affecting body temperature, alertness, blood pressure, and vomiting.

When to interrupt dosage

The measure of Prolixin is contingent upon the diagnosed disorder, including Schizophrenia, Gilles de la Tourette's Syndrome and Sedation therapy. The amount of dosage is dependent upon the method of application (e.g. Tablet, film coated - Oral or Intramuscular) featured in the table underneath.

Condition

Dosage

Administration

Depression

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Schizophrenia

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Sedation therapy

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Tourette Syndrome

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Chorea

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Sedation

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Huntington Disease

, 5.0 mg/mL, 0.5 mg/mL, 2.5 mg, 5.0 mg, 10.0 mg, 1.0 mg, 25.0 mg/mL, 2.5 mg/mL, 2.0 mg, 125.0 mg/mL, 100.0 mg/mL

Solution, concentrate - Oral, Oral, Solution, concentrate, , Elixir - Oral, Elixir, Tablet, film coated, Tablet, film coated - Oral, Intramuscular; Subcutaneous, Injection, solution, Injection, solution - Intramuscular; Subcutaneous, Tablet - Oral, Tablet, Injection, solution - Intramuscular, Liquid, Liquid - Intramuscular; Subcutaneous, Injection, Injection - Intramuscular; Subcutaneous, Intramuscular, Liquid - Intramuscular, Solution, Solution - Intramuscular; Subcutaneous

Warnings

Prolixin has seven contraindications, so it should not be taken in cases of the conditions specified in the following table.

Prolixin Contraindications

Condition

Risk Level

Notes

Brain Injuries

Do Not Combine

Disease

Do Not Combine

Liver Damage

Do Not Combine

Mental Depression

Do Not Combine

Hypnotics

Do Not Combine

Brain Injuries

Do Not Combine

Coma

Do Not Combine

There are 20 known major drug interactions with Prolixin.

Common Prolixin Drug Interactions

Drug Name

Risk Level

Description

Amisulpride

Major

Fluphenazine may increase the antipsychotic activities of Amisulpride.

Astemizole

Major

The metabolism of Astemizole can be decreased when combined with Fluphenazine.

Azelastine

Major

Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Dacomitinib

Major

The metabolism of Dacomitinib can be decreased when combined with Fluphenazine.

Deutetrabenazine

Major

The risk or severity of adverse effects can be increased when Fluphenazine is combined with Deutetrabenazine.

image of a doctor in a lab doing drug, clinical research

Prolixin Novel Uses: Which Conditions Have a Clinical Trial Featuring Prolixin?

640 active studies are examining the potential of Prolixin in providing relief for Huntington Disease, Sedation therapy and Chorea.

Condition

Clinical Trials

Trial Phases

Sedation therapy

0 Actively Recruiting

Sedation

2 Actively Recruiting

Early Phase 1, Not Applicable

Tourette Syndrome

0 Actively Recruiting

Depression

269 Actively Recruiting

Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3

Huntington Disease

3 Actively Recruiting

Not Applicable, Phase 1, Phase 2

Chorea

0 Actively Recruiting

Schizophrenia

32 Actively Recruiting

Early Phase 1, Not Applicable, Phase 4

Prolixin Reviews: What are patients saying about Prolixin?

5

Patient Review

11/6/2013

Prolixin for Mental Disorder with Loss of Normal Personality & Reality

I haven't had any problems since I started this treatment.

4.3

Patient Review

12/13/2008

Prolixin for Schizophrenia

3.3

Patient Review

7/6/2009

Prolixin for Schizophrenia

My son is on the prolixin injection and he says it's making him depressed. He's 17 years old and was diagnosed with paranoid schizophrenia. He believes that he doesn't need this medication.

1

Patient Review

9/3/2009

Prolixin for Mental Disorder with Loss of Normal Personality & Reality

I was given Prolixin injections a few years ago, and I told the doctor that I was having bad side effects. He gave me another injection anyway, and I had a seizure and then things got worse. I ended up being paralyzed for several months and had to learn how to walk and talk again. When the institution realized they couldn't take care of me, they placed me in an old folks home where I didn't receive any therapy. I had to do it all on my own, which was really tough since I was only about 37 at the time - by far the youngest person in the home.

1

Patient Review

5/23/2009

Prolixin for Mental Disorder with Loss of Normal Personality & Reality

I was pleased to find that this medication stopped the voices I was hearing. However, now I am struggling with side effects like an inability to sit still and constant pacing. If anyone else has experienced this, please let me know how you coped or what alleviated the symptoms. Thank you!

Patient Q&A Section about prolixin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug prolixin used for?

"Fluphenazine is a medication that treats schizophrenia. It works by rebalancing the levels of dopamine in the brain, which improves thinking, mood, and behavior."

Answered by AI

What is the side effects of prolixin?

"The following side effects may occur: drowsiness, lethargy, dizziness, lightheadedness, nausea, loss of appetite, sweating, dry mouth, blurred vision, headache, and constipation. If any of these effects persist or worsen, tell your doctor or pharmacist."

Answered by AI

Is prolixin still used today?

"This medication is only available in generic form since the brand name Prolixin has been discontinued."

Answered by AI

Is prolixin the same as Haldol?

"Prolixin is less likely to cause weight gain or sedation, but may cause movement disorders. It can help stabilize mood in people with schizophrenia or psychosis."

Answered by AI

Clinical Trials for Prolixin

Image of The Korean Association of West Florida in Tampa, United States.

Mobile App Mindfulness for Mental Health

18+
All Sexes
Tampa, FL

The goal of this clinical trial (single-arm pilot trial) is to learn whether a mobile application-based mindfulness intervention can improve mental health outcomes in older Korean immigrants aged 60 years and older. The main questions it aims to answer are whether the 8-week mobile app-based mindfulness intervention is feasible and acceptable, as indicated by recruitment, retention, and adherence rates, and whether participation in the intervention leads to improvements in positive psychological well-being (e.g., positive affect, optimism, life engagement, and mindfulness) and reductions in adverse mental health outcomes (e.g., anxiety, depressive symptoms, and perceived stress). Participants will complete baseline and post-intervention assessments, receive training on how to use the mobile mindfulness application, engage with the app for approximately 8 weeks (recommended 10-15 minutes per day), and participate in weekly check-ins to support engagement and address any challenges encountered during the intervention.

Waitlist Available
Has No Placebo

The Korean Association of West Florida (+1 Sites)

Soonhyung Kwon

Image of Brown University in Providence, United States.

Mindfulness-Based Intervention for Mental Health

18 - 24
All Sexes
Providence, RI

The goal of this clinical trial (single-arm feasibility study) is to examine the feasibility, acceptability, and preliminary efficacy of a mindfulness-based, app-delivered intervention to address mental health and emotion regulation challenges in young adults with early life adversities (ELAs). The main questions it aims to answer is: \- Will young adults find the Growth, Empowerment, and Mindfulness (GEM) intervention to be both feasible and acceptable, as demonstrated by participants' engagement and quantitative/qualitative feedback? Additionally, it aims to answer: * Will GEM intervention demonstrate preliminary efficacy in improving outcome measures including depression, anxiety? * Are improvements in mindfulness and sleep, as well as reductions in rumination, mechanisms of action underlying the improvements in psychological and behavioral outcomes of the intervention? Participants will be asked to: * participate in GEM, which integrates app-based intervention content, formal and informal mindfulness practices, weekly Zoom group sessions, and ecological momentary intervention (EMI) delivery * complete baseline, post-intervention, and 3-month follow-up assessments * complete weekly assessments and daily ecological momentary assessments (EMAs) during the intervention delivery * wear Fitbit for researchers to collect sleep-related data

Recruiting
Has No Placebo

Brown University

Shufang Sun, PhD

Image of Michael E. DeBakey VA Medical Center, Houston, TX in Houston, United States.

Behavioral Activation-Guided Self-Help for Depression

18+
All Sexes
Houston, TX

Symptoms of depression are highly prevalent among Veterans. However, fewer than 30% of individuals with these symptoms receive any psychotherapy in the Veterans Health Administration (VHA). This is due to many factors, which may include provider availability and patient preferences. Guided self-help (GSH), which involves coaching sessions with patients who are following a fully developed self-help program, has the potential to increase access to care for these Veterans, particularly if implemented within a stepped care model of mental health treatment delivery and if delivered by a diverse set of providers. The VHA's primary care-mental health integration (PCMHI) service, which focuses on short courses of care for mild to moderate symptoms, may be an ideal place in which to deploy GSH. The current project seeks conduct a pilot randomized trial of a GSH program for depression adapted for PCMHI based on behavioral activation.

Waitlist Available
Has No Placebo

Michael E. DeBakey VA Medical Center, Houston, TX

Maribel Plasencia, BA MS PhD

Have you considered Prolixin clinical trials?

We made a collection of clinical trials featuring Prolixin, we think they might fit your search criteria.
Go to Trials
Image of UC San Diego Health Psychiatry in San Diego, United States.

Medi-TBS for Depression

18 - 65
All Sexes
San Diego, CA

Repetitive Transcranial Magnetic stimulation (rTMS) is an FDA-approved therapy for treatment resistant depression (TRD) that involves brief magnetic stimulation pulses on the dorsolateral prefrontal cortex (DLPFC) brain region. But studies of rTMS alone show remission rates of \~30%. Additionally, rTMS has not been shown to improve cognitive functioning that may be an independent factor predicting treatment success. This study will develop a novel multimodal treatment, which combines intermittent theta burst stimulation (iTBS) - a type of rTMS with digital mindfulness training to engage brain plasticity, enhance cognition and alleviate depression symptoms in individuals with TRD.

Phase 2
Recruiting

UC San Diego Health Psychiatry

Image of UF World Equestrian Center in Ocala, United States.

ONE-D TMS + D-Cycloserine for Depression and Concussion

18 - 65
Female
Ocala, FL

Concussion and depression have long been recognized to be intertwined pathologies.1-3 Although female athletes are more likely to suffer from mental health symptoms than males athletes following a concussion,2 research in this area has been largely biased toward males.4 Recently functional MRI (fMRI) studies5 in concussed athletes have established that there are patterns of local alterations in neural connectivity in the frontal cortex that demonstrate anatomic congruency with transcranial magnetic stimulation (TMS) studies that mapped alternations in neural connectivity to functional and somatic symptoms.6 Thus, there is potential that TMS treatment could decrease both symptom profiles, revolutionizing comorbid treatment options. Possible Benefits: Previous studies have showed a 70% remission rate for depression symptoms. It is possible that participants could have improvement in depressive or concussive symptoms after the ONE-D TMS treatment.

Phase 2 & 3
Waitlist Available

UF World Equestrian Center

Sara Gould, MD

Have you considered Prolixin clinical trials?

We made a collection of clinical trials featuring Prolixin, we think they might fit your search criteria.
Go to Trials
Image of Northwestern University in Chicago, United States.

Mothers and Babies Program for Depression in Parents of Children With Down Syndrome

18+
All Sexes
Chicago, IL

Goal: This R34 study will pilot an adaptation for the Mothers and Babies (MB) program for expectant and new parents of infants with Down syndrome (MBDS). Background: Expectant and new parents of infants with Down syndrome are at high risk for perinatal depression. Perinatal depression is both independently, and exponentially associated with long-term adverse neurodevelopmental consequences for infants with Down syndrome. MB is a cognitive-behavioral intervention designed to prevent perinatal depression. MB as one of the two most effective counseling interventions for perinatal depression prevention, with moderate to large effects sizes found across a series of randomized controlled trials (RCTs). However, research suggests that expectant and new parents of children with Down syndrome may have needs that standard MB does not address. Significance: This project will pilot a Down syndrome adaptation to MB, MBDS designed to target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant. Innovation: The proposed project is innovative in three ways. First, the investigators plan to conduct the first pilot of a perinatal depression prevention intervention specifically designed for expectant and new parents of infants with Down syndrome. Second, the investigators plan to include fathers, nonbinary, and transgender parents to target symptoms of depression, rather than as simply a support person for maternal depressive symptom reduction. Third, the investigators plan to use a group format to establish cohorts of families of infants with Down syndrome of similar developmental stages. Design: Human-centered design and an open trial will inform a subsequent small randomized controlled clinical pilot to test the feasibility of the study protocol in preparation for a larger randomized controlled trial (RCT). Population: New and expectant parents of infants with Down syndrome. Outcomes: All aspects of the study protocol (e.g., condition allocation, treatment and control condition procedures, data collection, etc.) will be operationalized in preparation for the subsequent RCT. The investigators will assess MBDS effectiveness on target mechanisms of grief/loss and social support; and assess whether changes in the target mechanisms are associated with changes in depressive symptoms and parental sensitivity and responsivity to the infant.

Waitlist Available
Has No Placebo

Northwestern University

Heather J Risser

Image of San Diego State University in San Diego, United States.

Sleep Health Program for Marines

18+
All Sexes
San Diego, CA

The goal of this study is to test a sleep health program designed specifically for U.S. Marine Corps personnel. Researchers want to determine if this program helps Marines improve the participants sleep quality and overall mental health. The study will evaluate whether the program improves sleep quality and duration and reduces symptoms of depression, anxiety, PTSD, and suicide ideation. There are three distinct sleep health programs that will be evaluated; participants will be randomly assigned to one of five groups to receive different combinations of the sleep health programs. To measure results, researchers will use participant surveys for all enrolled participants and wearable sleep-tracking devices for a sub-set of participants. The study team expects that Marines who receive the most comprehensive version of the program will show the greatest improvements in sleep and psychological well-being.

Phase 2
Recruiting

San Diego State University

Emily Schmied, PhD

Image of University of Michigan in Ann Arbor, United States.

Virtual Reality for Depression in Multiple Sclerosis

18+
All Sexes
Ann Arbor, MI

This trial explores the use of immersive virtual reality (VR) nature-based experiences as a supplementary treatment for depression in individuals with progressive multiple sclerosis (MS). This study will evaluate the feasibility and efficacy of at-home VR deployment using the Apple Vision Pro, an advanced device that offers enhanced resolution, immersion, and usability compared to earlier VR systems. The study hypotheses include: * The integration of VR nature-based experiences with standard care will be feasible, acceptable, and will result in greater reductions in depressive symptoms compared to standard care or VR-only interventions. * The integration of VR nature-based experiences with standard care will result in greater reductions in stress and anxiety, better sleep, less insomnia, and improved fatigue compared to standard care alone or VR-only interventions.

Recruiting
Has No Placebo

University of Michigan

Hala Darwish, PhD

Apple Inc.

Have you considered Prolixin clinical trials?

We made a collection of clinical trials featuring Prolixin, we think they might fit your search criteria.
Go to Trials